logo
Share SHARE
FONT-SIZE Plus   Neg

AnaptysBio Inc. (ANAB) Has Soared To A New High On Phase 2 Study Results

AnaptysBio Inc. (ANAB) reported positive results from its Phase 2a trial of ANB020 Tuesday morning. An Eczema Area Severity Index score improvement of 50 percent relative to enrollment baseline was observed in 75 percent of patients after a single dose.

AnaptysBio has gapped open dramatically higher this morning and is now up 17.47 at $52.47 on above average volume. The stock has jumped to a new high for the year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
Follow RTT